<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302872</url>
  </required_header>
  <id_info>
    <org_study_id>EU010513, AU220816</org_study_id>
    <nct_id>NCT02302872</nct_id>
  </id_info>
  <brief_title>Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation</brief_title>
  <acronym>MAVERIC</acronym>
  <official_title>Mitral Valve Repair Clinical Trial (MAVERIC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mvrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mvrx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and performance of the ARTO System in
      patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Event Rate to 30 Days post-procedure</measure>
    <time_frame>&lt;=30 days post procedure</time_frame>
    <description>Major Adverse Events defined as: death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke, renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitral regurgitation grade and change from baseline to 30 days</measure>
    <time_frame>&lt;=30 days post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Technical Success</measure>
    <time_frame>procedural</time_frame>
    <description>At exit from cath lab, alive, with Successful access, delivery and retrieval of the device delivery system, and Deployment and correct positioning (including repositioning/recapture if needed) of the single intended device, and No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>ARTO system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARTO System</intervention_name>
    <arm_group_label>ARTO system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is ambulatory, able and willing to comply with the study protocol and has provided
             written informed consent

          2. Age ≥ 18

          3. Trans-septal catheterization is determined to be feasible by the treating physician

          4. NYHA class II-IV heart failure of any etiology

          5. Symptomatic with MR grade ≥ 2+

          6. LVEF ≥20% ≤ 50%

          7. LVEDD &gt; 50 mm and ≤ 70 mm

          8. No anticipated change in patient's cardiac medication regimen anticipated throughout
             the course of the study.

          9. • In the opinion of the investigator and heart surgery team, the patient is not a
             candidate for surgery, and the use of the ARTO™ System is technically feasible.

        Exclusion Criteria:

          1. In the opinion of the Investigator, the femoral vein and internal jugular vein cannot
             accommodate a 16 F catheter or the presence of an inferior vena cava (IVC) filter
             would interfere with advancement of the catheter or ipsilateral DVT is present

          2. Significant structural abnormality of the mitral valve (e.g., flail, prolapse, leaflet
             calcification)

          3. Significant mitral annular calcification

          4. Hemodynamic instability (systolic pressure &lt; 90 mmHg without afterload reduction or
             cardiogenic shock or the need for inotropic support or intra-aortic balloon pump)

          5. Prior mitral valve surgery or valvuloplasty or any currently implanted prosthetic
             valve or VAD

          6. History of, or active, rheumatic heart disease

          7. History of Atrial Septal Defects (ASD), whether repaired or not

          8. History of previously repaired PFO or PFO associated with clinical symptoms (e.g.,
             cerebral ischemia) within 6 months of the planned investigational procedure

          9. In the opinion of the investigator, an atrial septal aneurysm is present that may
             interfere with transseptal crossing

         10. Biventricular pacing initiated or anticipated within 6 months of the planned
             investigational procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrejs Erglis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pauls Stradins Clinical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Chang</last_name>
    <phone>+16506782960</phone>
    <email>rchang@mvrxinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>samantha greene</last_name>
    <phone>+19499108948</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Rafter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Rafter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Andrews Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Worthley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICPS</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Garot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Redwood, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Latvia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

